# Kymera Therapeutics to Participate in Upcoming March Investor Conferences
Canonical URL: https://biopharmsignal.com/news/KYMR/kymera-therapeutics-to-participate-in-upcoming-march-investor-conferences-0a48e13d
Ticker: KYMR
Company: Kymera
Source: Kymera
Published: 2026-02-24 12:00 EST
## Summary

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new...

## Article Body
Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events:

TD Cowen 46 th Annual Healthcare Conference in Boston, MA on March 3 at 9:10 a.m. ET;

Leerink Partners Global Healthcare Conference in Miami, FL on March 10 at 11:20 a.m. ET; and

Barclays 28 th Annual Global Healthcare Conference in Miami, FL on March 12 at 9:30 a.m. ET.

In addition, the Company will participate in the UBS Biotech Summit Miami and Jefferies Biotech on the Beach Summit on March 9 and March 11, respectively.

Live webcasts of the presentations will be available under “ News and Events ” in the Investors section of the Company’s website at www.kymeratx.com . Replays of the webcasts will be archived and available following the events.

About Kymera Therapeutics Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X or LinkedIn .

Investor Contact: Justine Koenigsberg Vice President, Investor Relations investors@kymeratx.com 857-285-5300

Media Contact: Matthew Henson Vice President, Corporate Communications mhenson@kymeratx.com 857-285-5300
## Recent Company News
- 2026-07-27 20:01 EST — [Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer](https://biopharmsignal.com/news/KYMR/kymera-therapeutics-appoints-terence-rooney-md-as-chief-medical-officer-93d7b265) — Source: Kymera
- 2026-07-07 11:00 EST — [Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader](https://biopharmsignal.com/news/KYMR/kymera-therapeutics-appoints-elizabeth-laws-ph-d-as-senior-vice-president-global-f322a3cc) — Source: Kymera
- 2026-06-25 11:00 EST — [Kymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial of KT-621 in Atopic Dermatitis with Topline Data by Year-end 2026](https://biopharmsignal.com/news/KYMR/kymera-therapeutics-completes-enrollment-in-the-phase-2b-broaden2-trial-of-kt-62-eddcfec5) — Source: Kymera
- 2026-06-24 20:01 EST — [Kymera Therapeutics Appoints Felix J. Baker, Ph.D., as Chairman of the Board of Directors](https://biopharmsignal.com/news/KYMR/kymera-therapeutics-appoints-felix-j-baker-ph-d-as-chairman-of-the-board-of-dire-f3d892d4) — Source: Kymera
- 2026-06-12 11:00 EST — [Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting](https://biopharmsignal.com/news/KYMR/kymera-therapeutics-presents-phase-1-data-in-healthy-japanese-adults-for-kt-621--a0403465) — Source: Kymera
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)